Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (NYSE: LLY) is ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Wall Street analysts who follow Viking and Summit expect further gains in 2025. Quick gains are often lost on Wall Street, ...

Tirzepatide treatment led to a 47% greater relative reduction in weight compared with semaglutide. Topline results were announced from a phase 3b clinical trial comparing tirzepatide with ...

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...

The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...

Hundreds of vials of black-market weight loss drugs have been seized from a home and two clinics in West Tennessee.

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...